GCAL® to triage COVID-19 patients and PETIA benefits
360Dx, a dedicated newsroom that covers emerging economic and technological trends in the clinical diagnostic market, has caught interest in the utility of calprotectin as a tool for risk assessment and prediction of clinical deterioration in COVID-19 patients.
360Dx has recently published an article that focuses on the recent results from the two AACC posters, confirming the value of calprotectin in severe COVID-19 disease. In the same article they also emphasises GCAL® 's (Gentian’s plasma and serum calprotectin assay) advantages being a particle-enhanced turbidimetric immunoassay (PETIA), compared to conventional enzyme-linked immunosorbent assays (ELISA).
Do you want to know more about our calprotectin and COVID-19 or our GCAL® immunoassay? If yes, please fill out the form below or send an email firstname.lastname@example.org and our Product Manager for GCAL® will contact you shortly.